Scientific article


Other titlePulmonology 2021: year in review
Published inRevue médicale suisse, vol. 18, no. 764, p. 64-68
Publication date2022-01-19

Among the new therapeutic developments in pulmonology during 2021, we have identified three topics of interest. A new biotherapy is now available for the management of severe uncontrolled non-Th2 asthma. In the field of pulmonary arterial hypertension, upfront triple therapy at the time of diagnosis is associated with a survival benefit in high-risk patients. Riociguat is a therapeutic option for patients that remain at intermediate risk despite treatment with iPDE5. Sotatercept, a promising new class of drug for treatment of group 1 PAH will soon be available. Finally, the use of transbronchial cryobiopsies as a valid alternative to surgical lung biopsy for the diagnosis of diffuse interstitial lung diseases will also be discussed in this review.

  • Biopsy
  • Humans
  • Lung
  • Lung Diseases, Interstitial
  • Pulmonary Medicine
Citation (ISO format)
RAYROUX, Caroline et al. Pneumologie. In: Revue médicale suisse, 2022, vol. 18, n° 764, p. 64–68. doi: 10.53738/REVMED.2022.18.764-65.64
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 07/01/2024
ISSN of the journal1660-9379

Technical informations

Creation03/10/2023 9:48:42 AM
First validation09/19/2023 10:08:26 AM
Update time09/19/2023 10:08:26 AM
Status update09/19/2023 10:08:26 AM
Last indexation01/18/2024 12:53:28 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack